Thu, 09 May 2019 14:27:34 GMT
Novartis acquires Takeda's dry eye drug for $5.3B
Novartis is acquiring the dry eye Xiidra drug from Takeda Pharmaceuticals in a deal valued at $5.3B, amid Swiss drugmaker's intention to renew the ophthalmic medicines portfolio.